Jupiter Topco LLC Acquires New Holdings in Xenon Pharmaceuticals Inc. $XENE

Jupiter Topco LLC acquired a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 4,186,519 shares of the biopharmaceutical company’s stock, valued at approximately $252,673,000. Jupiter Topco LLC owned approximately 4.33% of Xenon Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of XENE. BlackRock Inc. bought a new stake in Xenon Pharmaceuticals during the 2nd quarter valued at $454,057,000. Holocene Advisors LP bought a new position in shares of Xenon Pharmaceuticals in the 2nd quarter worth $56,637,000. Wellington Management Group LLP raised its position in shares of Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock worth $144,936,000 after acquiring an additional 1,435,096 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Xenon Pharmaceuticals by 1,968.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 862,300 shares of the biopharmaceutical company’s stock worth $38,650,000 after purchasing an additional 820,608 shares during the last quarter. Finally, Vestal Point Capital LP lifted its stake in shares of Xenon Pharmaceuticals by 53.8% during the 2nd quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock worth $62,600,000 after purchasing an additional 700,000 shares during the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Stock Up 5.6%

XENE opened at $63.79 on Thursday. Xenon Pharmaceuticals Inc. has a 52-week low of $35.60 and a 52-week high of $72.66. The company has a market cap of $6.17 billion, a P/E ratio of -13.46 and a beta of 0.62. The firm’s 50-day moving average price is $62.86 and its 200-day moving average price is $56.22.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.05. During the same quarter in the previous year, the business earned ($1.07) earnings per share. On average, research analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current fiscal year.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Gary Patou sold 1,322 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the completion of the transaction, the director owned 24,896 shares of the company’s stock, valued at approximately $1,322,973.44. This trade represents a 5.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Steven Gannon sold 10,000 shares of Xenon Pharmaceuticals stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $64.06, for a total transaction of $640,600.00. Following the sale, the director owned 1,870 shares of the company’s stock, valued at $119,792.20. The trade was a 84.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 12,512 shares of company stock worth $774,088. 2.91% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on XENE shares. Needham & Company LLC cut their target price on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. HC Wainwright restated a “buy” rating and issued a $74.00 price target on shares of Xenon Pharmaceuticals in a report on Monday, August 10th. Wall Street Zen raised shares of Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Royal Bank Of Canada reduced their price objective on shares of Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating for the company in a research note on Friday, August 7th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a report on Wednesday, May 27th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Xenon Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $77.13.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.